Cheraghi Mostafa, Namdari Mehrdad, Negahdari Babak, Eatemadi Ali
Department of Cardiology, Lorestan University of Medical Sciences, Khoramabad, Iran.
Department of Medical Biotechnology, School of Advanced Technologies in Medicine, Tehran University of Medical Sciences, Tehran, Iran.
Biomed Pharmacother. 2017 Mar;87:37-45. doi: 10.1016/j.biopha.2016.12.071. Epub 2016 Dec 29.
Myocardial infarction has been reported to be responsible for about 7.3 million deaths each year globally. Present treatments for myocardial infarction have been more palliative rather than curative. Over the past few years, stem cells have demonstrated its potency in regenerating damaged cardiac tissue, especially after myocardial infarction. However, limited short half-life of the protein and cell therapy and low transplanted cell survival rate as demonstrated via several clinical trials have lead to development of more potent and novel delivery systems like biomaterial delivery system and the use of various growth factors. In this review, we will be enumerating and discussing the recent advances in cardiac regeneration with focus on stem cell, biomaterial and growth factors.
据报道,全球每年约有730万人死于心肌梗死。目前针对心肌梗死的治疗更多是缓解症状而非治愈。在过去几年中,干细胞已显示出其在再生受损心脏组织方面的潜力,尤其是在心肌梗死后。然而,通过多项临床试验证明,蛋白质和细胞疗法的半衰期短以及移植细胞存活率低,导致了更有效和新颖的递送系统的发展,如生物材料递送系统以及各种生长因子的使用。在这篇综述中,我们将列举并讨论心脏再生的最新进展,重点是干细胞、生物材料和生长因子。